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The metastasis associated protein S100A4: a potential novel link
to inflammation and consequent aggressive behaviour of
rheumatoid arthritis synovial fibroblasts
Abstract
The metastasis-associated protein S100A4 belongs to the large family of S100 calcium-binding proteins
that appear to play regulatory roles in diverse biological activities. Moreover, a prognostic role of
S100A4 has been suggested for patients with several types of cancer. Cancer promoting properties for
S100A4 have been demonstrated, particularly through its regulation of cell motility, proliferation and
apoptosis, as well as by stimulation of angiogenesis and remodelling of the extracellular matrix.
Increased expression of S100A4 mRNA has been detected in proliferating synovial fibroblasts in
rheumatoid arthritis. Furthermore, strong upregulation of the S100A4 protein in rheumatoid arthritis
synovial tissue compared with osteoarthritis and control tissues has been demonstrated recently,
especially at sites of joint invasion. Several immune and vascular cells were also identified to be
producing S100A4 within the synovium. The local upregulation of S100A4 was accompanied by high
plasma and synovial fluid concentrations of the S100A4 protein existing in the bioactive oligomeric
form in patients with rheumatoid arthritis. Consistent with data from cancer studies, the extracellular
S100A4 oligomer appears to be involved in regulation of several matrix-degrading enzymes and
modulation of the transcriptional activation function of the tumour suppressor protein p53 in rheumatoid
arthritis synovial fibroblasts. Taken together, one can speculate that increased S100A4 protein in
circulation and locally at sites of inflammation, particularly at sites of joint destruction, might be linked
to the process of aggressive fibroblast behaviour contributing to the pathogenesis of chronic
autoinflammatory diseases such as rheumatoid arthritis.
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Abstract 
The metastasis-associated protein S100A4 belongs to the large family of calcium-binding 
proteins that appears to play regulatory roles in diverse biological activities. Moreover, a 
prognostic role of S100A4 has been suggested for patients with several types of cancer. 
Cancer promoting properties for S100A4 have been demonstrated, particularly through 
its regulation of cell motility, proliferation and apoptosis, as well as by stimulation of 
angiogenesis and remodeling of the extracellular matrix.  
Increased expression of S100A4 mRNA was detected in proliferating synovial fibroblasts 
in rheumatoid arthritis. Furthermore, strong up-regulation of S100A4 protein in 
rheumatoid arthritis synovial tissue compared with osteoarthritis and control tissues has 
been demonstrated recently, especially at the sites of joint invasion. Several immune and 
vascular cells were also identified to produce S100A4 within the synovium. The local up-
regulation of S100A4 was accompanied by high plasma and synovial fluid concentrations 
of the S100A4 protein existing in the bioactive oligomeric form in rheumatoid arthritis 
patients. Consistent with the data in cancer studies, the extracellular S100A4 oligomer is 
involved in regulation of several matrix degrading enzymes and modulates the 
transcriptional activation function of the tumor suppressor protein p53 in rheumatoid 
arthritis synovial fibroblasts.  
Taken together, one can speculate that increased S100A4 protein in circulation and 
locally at sites of inflammation, particularly at sites of joint destruction, might be 
implicated in the process of aggressive fibroblast behavior contributing to the 
pathogenesis of chronic autoinflammatory diseases such as rheumatoid arthritis.    
 
Key words: rheumatoid arthritis, S100A4, apoptosis, matrix degrading enzymes, 
synovial fibroblasts 
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Introduction 
The S100 proteins are small acidic calcium binding proteins (10-12 kD) that are found 
exclusively in vertebrates. The name of the whole group “S100” relates to its solubility in 
100% ammonium sulphate solution (1). This group consists of 20 members and is 
considered to be the largest subgroup of the EF-hand calcium binding protein family. 
S100 proteins share some structural similarities with the well known calcium-binding 
protein calmodulin and carry two calcium-binding EF-hand motifs with different 
affinities to bind calcium (2). It results in conformational changes of the proteins, leading 
to exposure of the hydrophobic surface that enables the S100 proteins to interact with a 
variety of target molecules (3). However the biological activity of some S100 proteins 
does not require calcium because it can also be regulated by zinc and copper (4).  
 
Originally, S100 proteins were identified in 1965 by Moore in bovine brain (1). Later it 
was shown that their biological activity appears to be dependent on the ability to form 
dimers (5). In the intracellular environment, most of S100 proteins exist as anti-parallel 
packed homodimers or heterodimers. Certain conditions, particularly the extracellular 
milieu, contribute to the formation of oligomers and multimers of some S100 proteins. 
For instance, S100A8/S100A9 forms heterotetramers (6,7), S100A12 hexamers (6,8), and 
S100A4 tetra- and higher-mers (9). Interaction of S100 proteins with several target 
proteins might explain their implication in a wide range of cellular events. Most of the 
S100 proteins are synthesized and localized intracellularly and participate in the 
regulation of a variety of processes within the cells such as proliferation and 
differentiation, apoptosis, extracellular matrix remodeling and cell motility (5). 
Furthermore, several S100 proteins can be released from cells and their extracellular 
functions have been demonstrated. Once released into the extracellular space, they exert 
cytokine-like activities. Some of S100 proteins can trigger intracellular signaling 
pathways through the receptor for advanced glycation end products (RAGE) (10,11). For 
others, including S100A4, reliable receptor(s) remain to be identified (12). 
 
Numbers of human diseases are associated with an altered expression of S100 proteins. 
For example, certain S100 proteins have been studied in tumors (S100A1, S100A4, 
S100A6, S100A7, S100P and S100B), neurodegenerative (S100B, S100A6, S100A12), 
cardiovascular (S100A8/9, S100A4, S100A1), pulmonary (S100A4) and inflammatory 
diseases (S100A8/9, S100A12, S100A7, S100A4), diabetes mellitus (S100A12), and 
allergies (S100A12) (13-22, summarized in 5). Whereas many S100 proteins exist, 
several, including S100A2, S100A4, S100A6, S100A7, S100P and S100B, have been 
found to be involved in tumor progression, while others, like S100A8, S100A9, and 
S100A12 are more likely related to inflammation. Since chronic inflammatory processes 
perpetuated by the immune system may abet tumor development (23), it can be suggested 
that certain members of S100 protein family might represent a bridge between cancer and 
inflammation. Although the association between S100A4 and cancer promoting 
properties has been established (24-26), its potential role in chronic inflammatory 
diseases such as rheumatoid arthritis (RA) is a more recent discovery (9,27,28). Here we 
summarize the current knowledge regarding S100A4 and its relation to the invasive 
behavior of cells involved in the destructive process of chronic inflammation.  
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Expression and function of S100A4 
S100A4 (also known as metastasin, pEL, p9Ka, FspI, CAPL and calvasculin) is a small 
11-kD protein that was originally isolated as a gene differentially expressed in highly 
metastatic mouse mammary adenocarcinoma cells (29). Subsequently, it was found also 
in normal tissues (30,31), however the physiological function of S100A4 is not yet 
understood. In rats, intracellular S100A4 protein was detected in smooth muscle and 
endothelial cells of blood vessels, epithelial cells, brown adipose and liver tissue, parietal 
cells of the stomach, neuronal cells and some immune cells within the spleen, thymus, 
and bone marrow (31,32). There is evidence that the expression of S100A4 is most likely 
related to different cancerous and immune processes (33). However, S100A4 has been 
found in normal human and rat tissues in fractions of T-lymphocytes, and neutrophils, 
while its expression is weak in monocytes, hair follicules and some others. S100A4 
protein has also been detected under chronic inflammatory conditions in macrophages, 
mast cells, neutrophils, certain T-cells, dendritic cells, and pericytes as well as activated 
synovial fibroblasts (9).  
 
Like other S100 proteins, S100A4 exerts intra- and extracellular effects and is involved in 
a number of cellular events. Several studies demonstrated that S100A4 may exist as 
homo- (S100A4/S100A4) or hetero-dimers (S100A4/S100A1) and also has a potential to 
form oligomers (34,35). Since, no enzymatic activity has been associated with S100A4, it 
is likely that interactions with other target proteins are critical for S100A4 activity. 
Intracellularly, S100A4 binds to several target molecules including the heavy chain of 
non-muscle myosin II (36) and liprin β1 (37), thereby modulating cell motility and 
adhesion. Furthermore, it interacts with the tumor suppressor protein p53 that may 
provide a link between S100A4 and apoptosis (30,36,38,39). Extracellular S100A4 has 
also been documented to stimulate neurite outgrowth of primary hippocampal neurons 
(40) and the migration of astrocytic tumor cells (41).Moreover, S100A4 is involved in 
angiogenesis (42) and remodeling of the extracellular matrix by means of up-regulation 
of proteolytic enzymes (28,43). In this regard Duarte et al. (44) proposed that S100A4 is 
a novel negative regulator of matrix mineralization that modulates the process of 
osteoblast differentiation. 
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Proposed function of S100A4 associated with tumor progression and metastasis 
In a complex cascade of events in tumorigenesis and metastatic progression, a variety of 
regulatory molecules are involved at different stages. Involvement of S100A4, as one of 
the regulatory elements, has been demonstrated in transgenic mice (26) as well as in 
humans (24,25). Both, intracellular (interaction with target proteins) and extracellular 
(cytokine-like triggering of signal transduction) forms of S100A4 contribute to the 
metastasis-promoting function of the protein.  
 
Intracellular S100A4 is known to interact with cytoskeletal components including the 
heavy chain of non-muscle myosin, non-muscle tropomyosin and F-actin (30,36,39), 
thereby affecting the motility of cancer cells. Interaction of S100A4 with the heavy chain 
of non-muscle myosin (MHC) results in inhibition of protein kinase C (PKC) and casein 
kinase (CK)-2 dependent phosphorylation of MHC (45,46). This interaction increases the 
solubility of myosin and regulates cytoskeletal dynamics. Similarly, binding of S100A4 
to non-muscle tropomyosin is also thought to be responsible for the disassembly of actin 
filaments (30). These data suggest that S100A4 can modulate the invasiveness of tumor 
cells. While these interactions have been documented to be calcium-dependent, there are 
some reports on calcium-independent interactions of S100A4 (for review see ref. 3). 
 
Besides cell motility, cell-cell adhesions are considered to be other properties of 
metastatic cells. Cooperation between S100A4 and E-cadherin (transmembrane 
glycoprotein that mediates Ca2+ dependent cell-cell adhesion) has been studied in mouse 
tumor cells as well as in humans. In both cases, an inverse correlation in the expression of 
E-cadherin and S100A4 was demonstrated, suggesting that the invasiveness of tumors 
expressing S100A4 could be induced by the abrogation of E-cadherin expression (47,48). 
Moreover, it has been proven that S100A4 contributes to cell adhesion via binding to 
liprin β1 (transmembrane tyrosine phosphatase-interacting protein), thus modulating 
LAR (transmembrane phosphotyrosine phosphatase)-dependent signaling directly 
involved in cell adhesion (37). 
 
S100A4 has also been reported to regulate proliferation and apoptosis. Recently, it was 
shown that the expression of S100A4 is associated with an increased amount of p53, 
however the conformational form of p53 was not studied (49). Moreover, physical 
interaction of S100A4 with the C-terminal regulatory domain of tumor suppressor protein 
p53 has been shown earlier (38). Induction of S100A4 in cell lines expressing wild type 
p53 modulated the expression of p53 downstream target genes including p21/WAF and 
bax (38). It has been suggested that S100A4 can enhance p53-dependent apoptosis and 
thereby accelerate the loss of wild type p53 functions, and consequently contribute to the 
development of a more aggressive phenotype during early tumor progression. Moreover, 
a reduced frequency of apoptosis was observed in the spleen of S100A4-/- animals after 
whole-body gamma-irradiation compared to wild-type animals (50). On the other hand, 
the extracellular S100A4 has been found to down-regulate bax in mouse adenocarcinoma 
cells, which might increase tumor cell survival. Both oligomeric and dimeric forms of 
S100A4 exerted equal inhibitory effect on the transcription of bax, however, no influence 
on the expression of p21/waf was observed (51).  
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Another important hallmark of invasive tumor growth and cancer metastasis is 
angiogenesis. S100A4 has been detected to exert its role in angiogenesis particularly via 
the modulation of the expression of thrombospondin 1 and matrix metalloproteinases 
(MMPs). Thrombospondin 1 belongs to the class of extracellular matrix glycoproteins 
with anti-angiogenic effects that can repress the progression of tumors (52). Thus, the 
treatment of tumor and endothelial cells with S100A4 oligomer induced down-regulation 
of thrombospondin 1 gene expression (38,51). Moreover, the S100A4 oligomer was 
capable of stimulating angiogenesis by promoting the chemotactic motility of endothelial 
cells in vitro, and of inducing corneal neovascularization in vivo (51). Dysregulation of 
MMPs participates in remodeling of the extracellular matrix, tumor cell migration and 
invasion (53). An association between S100A4 and the production of MMPs has also 
been reported (38,43,51). Extracellular S100A4 strongly stimulated the proteolytic 
activity in endothelial and tumor cells, particularly by up-regulating MMP-13. In a highly 
metastatic osteosarcoma cell line transfected with a specific ribozyme against the 
S100A4 gene transcript, the down-regulation of S100A4 expression resulted in a 
reduction of the mRNA levels of MMP-2, MMP-14, and the endogenous tissue inhibitor 
TIMP-1 (54). In addition, the suppression of S100A4 has been shown to reduce 
significantly the expression and proteolytic activity of MMP-9 (55).  
 
Summarizing the abovementioned data, one can support the idea that the metastasis-
inducing S100A4 plays a pivotal role in modulating the tumor stroma (51), because it has 
been shown that S100A4 is involved in the regulation of cancer invasiveness and 
metastasis (summarized in 56). Both intracellular as well as extracellular functions of 
S100A4 have been proposed to be involved in this process, and the protein was suggested 
as a prognostic marker for several tumors (33). 
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Proposed function of S100A4 in rheumatoid arthritis 
Rheumatoid arthritis (RA) is an autoimmune disease characterized by bone and cartilage 
destruction, chronic synovial inflammation and hyperplasia. In recent years, synovial 
fibroblasts (SF) have been suggested to play an active role in the pathogenesis of RA 
(57,58). Masuda et al. (59) found certain genes, including S100A4, to be up-regulated in 
proliferating compared with non-proliferating RA-SF. Moreover, S100A4 mRNA has 
been detected both in the lining as well as sublining layer of RA synovial tissues, while 
its expression was not observed in healthy synovial tissues. Recently, we have 
demonstrated a strong up-regulation of S100A4 protein in RA compared with 
osteoarthritis (OA) and control synovial tissues (9,28). Most importantly, the expression 
of S100A4 protein has been detected at sites of cartilage and bone destruction. Synovial 
fibroblasts, as well as several immune and vascular cells, were identified to produce 
S100A4 (9). In comparison with other S100 proteins such as S100A7, S100A8, S100A9 
and S100A12, the majority of cells in RA synovial tissue have been found to express 
S100A4. The up-regulation of S100A4 in RA synovial tissue was consistent with the 
finding of rather high concentrations of the protein in RA compared with OA plasma 
(1100 vs. 211 ng/ml) and synovial fluid (1980 vs. 247 ng/ml) (Fig.1). In plasma and 
synovial fluid of RA patients, S100A4 exists in a bioactive oligomeric conformation 
whereas in OA the majority of extracellular S100A4 was detected in the less active, 
dimeric form. Consistent with observations in tumor models, extracellular S100A4 
induced the up-regulation of several MMPs such as MMP-1, MMP-3, MMP-9, and 
MMP-13 (28) and stabilized the tumor suppressor protein p53 in RA-SF (9). The active 
oligomeric S100A4 protein also revealed notable effects on the transcriptional regulation 
of p53 target genes including Bcl-2, p21/WAF and HDM2 that are involved in 
proliferation and apoptosis.  
 
Taken together, S100A4 is increased in patients with RA both locally at sites of 
inflammation, as well as systemically in circulation. Moreover expression of S100A4 is 
localized specifically at sites of joint destruction and was shown to modulate in vitro 
proliferation, apoptosis and the production of several MMPs in RA synovial fibroblasts 
(Fig.2).  
 
Recently, the potential implication of S100A4 has also been studied in the pathogenesis 
of OA (60). Enhanced expression of S100A4 compared with normal tissue was detected 
by immunohistochemistry and western blot in cartilage from OA patients and in a human 
articular chondrocyte cell line. Richard Loeser’s group demonstrated that S100A4 binds 
to multiligand RAGE and thereby stimulates the expression of MMP-13 in human 
articular chondrocytes. Activation of RAGE by S100A4 in chondrocytes triggers signal 
transduction pathways stimulating phosphorylation of Pyk-2 and MAP kinases (ERK-1/2, 
p38, and JNK), the activation of NF-κB and the production of reactive oxygen species 
(ROS). These data suggest that S100A4-RAGE signaling might be involved in the 
process of cartilage degeneration in OA (60). It appears that S100A4 is involved in 
numerous processes leading to joint destruction.   
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Proposed function of other S100 proteins in rheumatoid arthritis 
Within the S100 protein family a subgroup of phagocyte-specific proteins (calgranulins) 
has been identified. The three members of this subgroup, S100A8, S100A9 and S100A12 
are predominantly expressed in cells of myeloid origin and exert proinflammatory 
functions in the extracellular milieu via interaction with RAGE (11,61-63). Their 
elevated levels have been associated with a number of inflammatory diseases, particularly 
with rheumatoid arthritis.  
 
S100A12 (calgranulin C or EN-RAGE) is mainly detected in granulocytes (64) and in 
lower levels in monocytes (3). However, increased levels of S100A12 in inflamed tissues 
have also been documented in a number of disorders including psoriasis (65,66), 
inflammatory bowel diseases (11,67), Kawasaki disease (68,69), giant cell arteritis (70), 
type 2 diabetes (71) and Alzheimer disease (72). 
 
The results from in vitro studies and animal models have revealed the impact of S100A12 
in the pathogenesis of chronic arthritis. S100A12 has been immuno-detected within the 
synovial-sublining layer, the perivascular region and the synovial-lining layer in RA. 
Staining of sequential sections of the synovial lining-layer by CD68 confirmed 
occasional S100A12 positive macrophages (73). S100A12 may stimulate the 
accumulation of neutrophils by inducing their release from the bone marrow as well as by 
activating their adhesion and migration toward inflammatory sites (74). In early stages of 
inflammation, binding of S100A12 to RAGE may lead to stimulation of endothelial cells 
by increasing surface expression of adhesion molecules (VCAM-1, ICAM-1) and to 
promotion of transendothelial migration of phagocytes (75). Furthermore, S100A12 up-
regulates NF-κB driven transcription of some inflammatory cytokines such as tumor 
necrosis factor (TNF) -α in inflammatory cells (11). Increased levels of S100A12 were 
found in synovial fluid and plasma from patients with RA, gout and psoriatic arthritis, 
however, they were undetectable in patients with non-inflammatory disorders such as OA 
(74). Foell et al. (76) found in juvenile idiopathic arthritis (JIA) that the S100A12 serum 
concentration correlates with disease activity and it decreases in response to different 
anti-inflammatory therapies. Moreover elevated serum S100A12 could be detected weeks 
before clinically apparent relapses in patients with previously well controlled disease.  
 
The other calgranulins, S100A8 (MRP8 or calgranulin A) and S100A9 (MRP14 or 
calgranulin B) exist in general as a heterodimer and are actively secreted by human 
monocytes and activated granulocytes (77). The expression of S100A8 and S100A9 
without concomitant formation of their complex has been rarely found, e.g. in a chronic 
type of inflammatory reaction in glomerulonephritis or in chronic renal allograft rejection 
(78,79). Up-regulation of the S100A8/9 complex, known as calprotectin, however, has 
been well described in inflammatory disorders such as cystic fibrosis (80-83), psoriasis 
(84), tuberculosis (85), Crohn´s disease and ulcerative colitis (67). The presence of 
S100A8 and S100A9 in infiltrated macrophages in RA was detected in 1987 (86). The 
authors demonstrated that resting normal tissue macrophages did not express both MRP-8 
and MRP-14, macrophages in acutely inflamed tissues expressed MRP-14 but not MRP-
8, and in chronic inflammation, infiltrated macrophages expressed both proteins. 
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Additionally, Youssef P et al. found predominant expression of MRP-8, MRP-14, and 
their heterodimer at the site of cartilage destruction in RA (87). Analysis of blood and 
synovial fluid showed significantly elevated levels of S100A8/9 in plasma and synovial 
fluid of patients with RA compared with OA (74,88). Moreover, concentrations of the 
dimer were significantly higher in synovial fluid than in serum, and they correlated with 
each other showing a strong association with disease activity, and it was suggested that 
MRP8/14 could be a parameter of prognostic value for further disease flare in patients 
with JIA (89,90). In vitro, the S100A8/A9 heterodimer may enhance inflammation 
through increased production of proinflammatory cytokines including TNF-α (91). In 
addition to chronic inflammation, most recent data point to the fact that the MRP8/14 
dimer is associated with the development of acute coronary syndrome. Because its blood 
levels increase before the levels of markers of myocardial necrosis, the MRP8/14 dimer 
might serve as a novel sensitive predictor of the syndrome (14). Based on the 
abovementioned data, one can suggest that both S100A12 and S100A8/A9 proteins are 
valuable markers of inflammation as well as potential targets for future therapies. 
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Conclusions 
Over the past decade, many data have produced great strides in understanding the role of 
S100A4 in tumor cell invasion and the subsequent metastasis. As shown by several 
research groups, the interaction of the protein with its several effectors can activate 
signaling pathways and modulate detachment of the extracellular matrix, adhesion, cell 
motility, angiogenesis, cell proliferation and apoptosis. Interestingly, hallmarks of 
metastatic activity of tumor cells and the invasive behavior of synovial fibroblasts in RA 
appear similar. Analogous to the environment of tumors, S100A4 has been found to be 
increased in inflamed synovial tissue and body fluids in patients with RA. S100A4 is 
proposed to be up-regulated upon synovial fibroblast activation/proliferation (59) as well 
as by several inflammatory cells that accumulate in RA synovial tissue (9,28). Thereby, 
we suggest that the S100A4 properties are not clearly RA-specific, however, can be 
related to systemic inflammation or/and activation of synovial fibroblasts.  Based on in 
vitro studies, S100A4 can up-regulate the production of matrix degrading enzymes and 
stabilize the tumor suppressor protein p53 in synovial fibroblasts (9,28). Thereby, it can 
be suggested that S100A4 takes part in stimulating cell proliferation, modulating 
apoptosis, and tissue remodeling and thereby contributes to the process of inflammation 
and tissue destruction. Further analysis and characterization of the molecular 
mechanisms of S100A4 regulating pathways are needed to clarify the contribution of 
S100A4 to the immune/inflammatory processes leading to synovial hyperplasia and 
inflammation. 
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Legends to figures: 
 
Figure 1 
Comparison between the S100A4 protein (Mts1) levels in plasma and synovial fluid from 
patients with rheumatoid arthritis and individuals with non-inflammatory knee 
osteoarthritis.  
 
Figure 2 
Postulated implications of S100A4 protein (Mts1) in the process of inflammation and 
joint destruction in rheumatoid arthritis. Increased amounts of the protein in both 
synovial tissue and synovial fluid may interact with resident cells and modulate the 
function of the tumor-suppressor protein p53 as well as the production of several matrix 
degrading enzymes.  
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